title: [Using the preparation "human immunoglobulin against herpes simplex virus type 1 for intramuscular injections" in the complex therapy of nervous system diseases].
abstract: The technology of obtaining of specific immunoglobulin for serotherapy of neuroinfection caused by virus herpes simplex 1 type was developed. The patients presented with the following diseases: arachnoencephalitis, encephalopolyradiculoneuritis, encephalomyelitis, encephalitis, arachnoiditis, polyneuropathy, encephalomyelopolyradiculoneuritis, meningoencephalitis. The study showed good tolerance and safety of the medicine, no adverse effects registered during the study. The assessed median score of the efficacy was 2.8 from 3. The obtained results suggest using the liquid form preparation for intramuscular injection "Immunoglobulin for treatment of neuroinfection caused by virus herpes simplex type 1". The Close corporation "Biofarma" located in Kyiv produces this medicine.
authors.forename: A O
authors.initials: AO
authors.lastname: Rudenko
authors.forename: N S
authors.initials: NS
authors.lastname: Diachenko
authors.forename: N V
authors.initials: NV
authors.lastname: Nesterova
authors.forename: K V
authors.initials: KV
authors.lastname: Kurishchuk
authors.forename: T H
authors.initials: TH
authors.lastname: Berestova
authors.forename: S D
authors.initials: SD
authors.lastname: Zahorodnia
authors.forename: L S
authors.initials: LS
authors.lastname: Riads'ka
authors.forename: L V
authors.initials: LV
authors.lastname: Muravs'ka
authors.forename: O H
authors.initials: OH
authors.lastname: Andrieieva
authors.forename: H V
authors.initials: HV
authors.lastname: Baranova
mesh_terms: D020805:Central Nervous System Viral Diseases / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D004334:Drug Administration Schedule; D006561:Herpes Simplex / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G